Molecular biology of burkitt lymphoma

Burkitt's Lymphoma

Volumn , Issue , 2013, Pages 211-226

  Giulino Roth, Lisa ^a,b   Cesarman, Ethel ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84976602249     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4313-1_11     Document Type: Chapter

References (85)

1. Burkitt D (1958) A sarcoma involving the jaws in African children. Br J Surg 46:218-223
2. Hutt MS, Burkitt D (1965) Geographical distribution of cancer in East Africa: a new clinico- pathological approach. Br Med J 2:719-722
3. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702-703
4. Piccaluga PP, De Falco G, Kustagi M et al (2011) Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 117:3596-3608
5. Haralambieva E, Schuuring E, Rosati S et al (2004) Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer 40:10-18
6. Hummel M, Bentink S, Berger H et al (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430
7. Lai JL, Fenaux P, Zandecki M, Nelken B, Huart JJ, Deminatti M (1989) Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. Ann Genet 32:26-32
8. Lones MA, Sanger WG, Le Beau MM et al (2004) Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol 26:169-178
9. Onciu M, Schlette E, Zhou Y et al (2006) Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer 107:1084-1092
10. Poirel HA, Cairo MS, Heerema NA et al (2009) Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non- Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia 23:323-331
11. Nelson M, Perkins SL, Dave BJ et al (2010) An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol 148:600-610
12. Vennstrom B, Sheiness D, Zabielski J, Bishop JM (1982) Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 42:773-779
13. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211-1217
14. McMahon SB, Wood MA, Cole MD (2000) The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20:556-562
15. God JM, Haque A (2010) Burkitt lymphoma: pathogenesis and immune evasion. J Oncol 2010. pii 516047
16. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M (1997) An alternative pathway for gene regulation by Myc. EMBO J 16:5672-5686
17. Smith K, Dalton S (2010) Myc transcription factors: key regulators behind establishment and maintenance of pluripotency. Regen Med 5:947-959
18. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676
19. Wernig M, Meissner A, Foreman R et al (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318-324
20. Dominguez-Sola D, Ying CY, Grandori C et al (2007) Non-transcriptional control of DNA replication by c-Myc. Nature 448:445-451
21. Dang CV, Enigmatic MYC (2010) Conducts MYC conducts an unfolding systems biology symphony. Genes Cancer 1:526-531
22. Gomez-Roman N, Grandori C, Eisenman RN, White RJ (2003) Direct activation of RNA polymerase III transcription by c-Myc. Nature 421:290-294
23. Arabi A, Wu S, Ridderstrale K et al (2005) c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7:303-310
24. Dang CV (2010) Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 70:859-862
25. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79:7824-7827
26. Taub R, Kirsch I, Morton C et al (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837-7841
27. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553-563
28. Ramiro AR, Jankovic M, Eisenreich T et al (2004) AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118:431-438
29. Robbiani DF, Bothmer A, Callen E et al (2008) AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135:1028-1038
30. Oliveira TY, Resch W, Jankovic M, Casellas R, Nussenzweig MC, Klein IA (2012) Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements. J Immunol Methods 375(1-2):176-181
31. Klein IA, Resch W, Jankovic M et al (2011) Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell 147:95-106
32. Shiramizu B, Barriga F, Neequaye J et al (1991) Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 77:1516-1526
33. Cesarman E, Dalla-Favera R, Bentley D, Groudine M (1987) Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 238:1272-1275
34. Siebenlist U, Hennighausen L, Battey J, Leder P (1984) Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell 37:381-391
35. Taub R, Moulding C, Battey J et al (1984) Activation and somatic mutation of the translocated c-myc gene in burkitt lymphoma cells. Cell 36:339-348
36. Spencer CA, LeStrange RC, Novak U, Hayward WS, Groudine M (1990) The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles. Genes Dev 4:75-88
37. Rabbitts TH, Hamlyn PH, Baer R (1983) Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 306:760-765
38. Showe LC, Ballantine M, Nishikura K, Erikson J, Kaji H, Croce CM (1985) Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma cell line that is translocated to a germ line alpha switch region. Mol Cell Biol 5:501-509
39. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I (1993) Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 5:56-61
40. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M (1993) Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 8:2741-2748
41. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95:2104-2110
42. Leucci E, Cocco M, Onnis A et al (2008) MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 216:440-450
43. Ambros V (2004) The functions of animal microRNAs. Nature 431:350-355
44. Onnis A, De Falco G, Antonicelli G et al (2010) Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 5(9). pii: e12960
45. Lombardi L, Newcomb EW, Dalla-Favera R (1987) Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 49:161-170
46. Polack A, Hortnagel K, Pajic A et al (1996) c-myc activation renders proliferation of Epstein- Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA 93:10411-10416
47. Pajic A, Staege MS, Dudziak D et al (2001) Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int J Cancer 93:810-816
48. Schlee M, Holzel M, Bernard S et al (2007) C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 120:1387-1395
49. Staege MS, Lee SP, Frisan T et al (2002) MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci USA 99:4550-4555
50. Adams JM, Harris AW, Pinkert CA et al (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538
51. Kovalchuk AL, Qi CF, Torrey TA et al (2000) Burkitt lymphoma in the mouse. J Exp Med 192:1183-1190
52. Wilda M, Bruch J, Harder L et al (2004) Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia 18:584-588
53. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT (1992) The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 52:4273-4276
54. Capoulade C, Bressac-de paillerets B, lefrere I et al (1998) Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16:1603-1610
55. Cherney BW, Bhatia KG, Sgadari C et al (1997) Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 57:2508-2515
56. Vousden KH, Crook T, Farrell PJ (1993) Biological activities of p53 mutants in Burkitt's lymphoma cells. J Gen Virol 74(Pt 5):803-810
57. Lindstrom MS, Klangby U, Wiman KG (2001) p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 20:2171-2177
58. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG (1998) p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680-1687
59. Stiegler P, Giordano A (1998) Big brothers are watching: the retinoblastoma family and growth control. Prog Mol Subcell Biol 20:25-42
60. Cinti C, Claudio PP, Howard CM et al (2000) Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 60:383-389
61. Cinti C, Leoncini L, Nyongo A et al (2000) Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am J Pathol 156:751-760
62. De Falco G, Bellan C, Lazzi S et al (2003) Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene 22:6214-6219
63. Lazzi S, Bellan C, De Falco G et al (2002) Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol 33:723-731
64. De Falco G, Leucci E, Lenze D et al (2007) Gene-expression analysis identifies novel RBL2/ p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood 110:1301-1307
65. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101:6164-6169
66. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5:189-200
67. Hemann MT, Bric A, Teruya-Feldstein J et al (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436:807-811
68. Kennedy G, Komano J, Sugden B (2003) Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 100:14269-14274
69. Hong M, Murai Y, Kutsuna T et al (2006) Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol 132:1-8
70. Yin Q, Flemington EK (2006) siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346:385-393
71. Saridakis V, Sheng Y, Sarkari F et al (2005) Structure of the p53 binding domain of HAUSP/ USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18:25-36
72. O'Nions J, Turner A, Craig R, Allday MJ (2006) Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 80:12408-12413
73. Lu J, Murakami M, Verma SC et al (2011) Epstein-Barr virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 410:64-75
74. Kelly G, Bell A, Rickinson A (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8:1098-1104
75. Kelly GL, Milner AE, Tierney RJ et al (2005) Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 79:10709-10717
76. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 90:8479-8483
77. Fanidi A, Hancock DC, Littlewood TD (1998) Suppression of c-Myc-induced apoptosis by the Epstein-Barr virus gene product BHRF1. J Virol 72:8392-8395
78. Kelly GL, Long HM, Stylianou J et al (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5:e1000341
79. Watanabe A, Maruo S, Ito T, Ito M, Katsumura KR, Takada K (2010) Epstein-Barr virus- encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol 84:2893-2901
80. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon
81. Dave SS, Fu K, Wright GW et al (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442
82. Lenze D, Leoncini L, Hummel M et al (2011) The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 25(12):1869-1876
83. Robertus JL, Kluiver J, Weggemans C et al (2010) MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol 149:896-899
84. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8:976-990
85. Delmore JE, Issa GC, Lemieux ME et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904-917